U.S. flag

An official website of the United States government

Display Settings:

Items per page
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 10

1.
Appendix Figure 6

Appendix Figure 6. Odds of congestive heart failure with thiazolidinediones and sulfonylureas. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. SU = sulfonylurea; TZD = thiazolidinedione.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

2.
Appendix Figure 3

Appendix Figure 3. Odds of fatal and nonfatal ischemic heart disease with metformin monotherapy and metformin plus rosiglitazone. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. Met = metformin; Rosi = rosiglitazone.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

3.
Figure 4

Figure 4. Pooled odds of mild or moderate hypoglycemia with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. DPP-4 = dipeptidyl peptidase-4 inhibitor; Meg = meglitinide; Met = metformin; SU = sulfonylurea; TZD = thiazolidinedione.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

4.
Figure 3

Figure 3. Pooled between-group differences in LDL-C levels with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. To convert LDL-C values to mmol/L, multiply by 0.0259. DPP-4 = dipeptidyl peptidase-4 inhibitor; LDL-C = low-density lipoprotein cholesterol; Met = metformin; Pio = pioglitazone; Rosi = rosiglitazone; SU = sulfonylurea.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

5.
Appendix Figure 2

Appendix Figure 2. Summary of evidence search and selection for systematic reviews. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

RCT = randomized, controlled trial.
*Total may exceed the number in the corresponding box because articles could be excluded for more than 1 reason at this level.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

6.
Appendix Figure 5

Appendix Figure 5. Pooled between-group differences in triglyceride levels with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. To convert triglyceride values to mmol/L, multiply by 0.0113. DPP-4 = dipeptidyl peptidase-4 inhibitor; Meg = meglitinide; Met = metformin; Pio = pioglitazone; Rosi = rosiglitazone; SU = sulfonylurea.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

7.
Appendix Figure 4

Appendix Figure 4. Pooled between-group differences in HDL-C levels with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. To convert HDL-C values to mmol/L, multiply by 0.0259. DPP-4 = dipeptidyl peptidase-4 inhibitor; HDL-C = high-density lipoprotein cholesterol; Meg = meglitinide; Met = metformin; Pio = pioglitazone; Rosi = rosiglitazone; SU = sulfonylurea.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

8.
Figure 2

Figure 2. Pooled between-group differences in body weight with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. basal = basal insulin; DPP-4 = dipeptidyl peptidase-4 inhibitor; GLP-1 = glucagon-like peptide-1; Meg = meglitinide; Met = metformin; Pio = pioglitazone; premixed = premixed insulin; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

9.
Figure 1

Figure 1. Pooled between-group differences in HbA1c level with monotherapy and combination therapies. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Error bars represent 95% CIs. basal = basal insulin; DPP-4 = dipeptidyl peptidase-4 inhibitor; HbA1c = hemoglobin A1c; Meg = meglitinide; Met = metformin; Pio = pioglitazone; premixed = premixed insulin; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

10.
Appendix Figure 1

Appendix Figure 1. Summary of evidence search and selection. From: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations.

Searches were done through April 2010. CENTRAL = Cochrane Central Database of Controlled Trials.
*Total may exceed the number in the corresponding box because articles could be excluded for more than 1 reason at this level.
†71 studies were included in the 2007 review.

Wendy L. Bennett, et al. Ann Intern Med. ;154(9):602-613.

CitationFull text

Display Settings:

Items per page

Supplemental Content

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center